JPMorgan analyst Jessica Fye reinstated coverage of Esperion with a Neutral rating and no price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ESPR:
- Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
- Esperion presents exploratory analysis of CLEAR Outcomes
- Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
- Biotech Alert: Searches spiking for these stocks today
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)